Literature DB >> 29870876

Histologic heterogeneity of triple negative breast cancer: A National Cancer Centre Database analysis.

Matthew N Mills1, George Q Yang1, Daniel E Oliver1, Casey L Liveringhouse1, Kamran A Ahmed1, Amber G Orman1, Christine Laronga2, Susan J Hoover2, Nazanin Khakpour2, Ricardo L B Costa2, Roberto Diaz3.   

Abstract

BACKGROUND: Triple negative breast cancer (TNBC) is an aggressive disease, but recent studies have identified heterogeneity in patient outcomes. However, the utility of histologic subtyping in TNBC has not yet been well-characterised. This study utilises data from the National Cancer Center Database (NCDB) to complete the largest series to date investigating the prognostic importance of histology within TNBC.
METHODS: A total of 729,920 patients (pts) with invasive ductal carcinoma (IDC), metaplastic breast carcinoma (MBC), medullary breast carcinoma (MedBC), adenoid cystic carcinoma (ACC), invasive lobular carcinoma (ILC) or apocrine breast carcinoma (ABC) treated between 2004 and 2012 were identified in the NCDB. Of these, 89,222 pts with TNBC that received surgery were analysed. Kaplan-Meier analysis, log-rank testing and multivariate Cox proportional hazards regression were utilised with overall survival (OS) as the primary outcome.
RESULTS: MBC (74.1%), MedBC (60.6%), ACC (75.7%), ABC (50.1%) and ILC (1.8%) had significantly different proportions of triple negativity when compared to IDC (14.0%, p < 0.001). TNBC predicted an inferior OS in IDC (p < 0.001) and ILC (p < 0.001). Lumpectomy and radiation (RT) were more common in MedBC (51.7%) and ACC (51.5%) and less common in MBC (33.1%) and ILC (25.4%), when compared to IDC (42.5%, p < 0.001). TNBC patients with MBC (HR 1.39, p < 0.001), MedBC (HR 0.42, p < 0.001) and ACC (HR 0.32, p = 0.003) differed significantly in OS when compared to IDC. CONCLUSION(S): Our results indicate that histologic heterogeneity in TNBC significantly informs patient outcomes and thus, has the potential to aid in the development of optimum personalised treatments.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Adenoid cystic breast cancer; Apocrine breast cancer; Breast; Breast neoplasms; Invasive ductal carcinoma; Invasive lobular carcinoma; Medullary breast cancer; Metaplastic breast cancer; Prognosis; Triple negative breast neoplasms

Mesh:

Year:  2018        PMID: 29870876     DOI: 10.1016/j.ejca.2018.04.011

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  21 in total

1.  Quantitative assessment of breast cancer liver metastasis expansion with patient-derived xenografts.

Authors:  Mohammad A Alzubi; Sahib S Sohal; Madhumitha Sriram; Tia H Turner; Patricija Zot; Michael Idowu; J Chuck Harrell
Journal:  Clin Exp Metastasis       Date:  2019-05-08       Impact factor: 5.150

2.  Varying outcomes of triple-negative breast cancer in different age groups-prognostic value of clinical features and proliferation.

Authors:  H Vihervuori; K Korpinen; T A Autere; H Repo; K Talvinen; P Kronqvist
Journal:  Breast Cancer Res Treat       Date:  2022-10-19       Impact factor: 4.624

Review 3.  Rare Breast Cancer Subtypes.

Authors:  Sarah Jenkins; Megan E Kachur; Kamil Rechache; Justin M Wells; Stanley Lipkowitz
Journal:  Curr Oncol Rep       Date:  2021-03-23       Impact factor: 5.075

4.  Vitamin D receptor (VDR) expression in different molecular subtypes of canine mammary carcinoma.

Authors:  R Sánchez-Céspedes; M D Fernández-Martínez; A I Raya; C Pineda; I López; Y Millán
Journal:  BMC Vet Res       Date:  2021-05-25       Impact factor: 2.741

5.  Clinical outcomes in patients with triple negative or HER2 positive lobular breast cancer: a single institution experience.

Authors:  Alicia Okines; Tazia Irfan; Bernice Asare; Kabir Mohammed; Peter Osin; Ashutosh Nerurkar; Ian E Smith; Marina Parton; Alistair Ring; Stephen Johnston; Nicholas C Turner
Journal:  Breast Cancer Res Treat       Date:  2022-02-04       Impact factor: 4.872

6.  Triple-negative breast lobular carcinoma: a luminal androgen receptor carcinoma with specific ESRRA mutations.

Authors:  Anthony Bergeron; Gaëtan MacGrogan; Aurélie Bertaut; Sylvain Ladoire; Patrick Arveux; Isabelle Desmoulins; Hervé Bonnefoi; Catherine Loustalot; Sophie Auriol; Françoise Beltjens; Emilie Degrolard-Courcet; Céline Charon-Barra; Corentin Richard; Romain Boidot; Laurent Arnould
Journal:  Mod Pathol       Date:  2021-03-22       Impact factor: 8.209

7.  CHARACTERISTICS AND PROGNOSIS OF TRIPLE-NEGATIVE BREAST CANCER PATIENTS: A CROATIAN SINGLE INstitution RETROSPECTIVE COHORT STUDY.

Authors:  Ana Tečić Vuger; Robert Šeparović; Ljubica Vazdar; Mirjana Pavlović; Petra Lepetić; Sanda Šitić; Žarko Bajić; Božena Šarčević; Damir Vrbanec
Journal:  Acta Clin Croat       Date:  2020-03       Impact factor: 0.780

8.  Rapid Synthesis of N-Tosylhydrazones under Solvent-Free Conditions and Their Potential Application Against Human Triple-Negative Breast Cancer.

Authors:  Zengyang Xie; Yuying Song; Lujia Xu; Yukun Guo; Min Zhang; Limei Li; Kai Chen; Xue Liu
Journal:  ChemistryOpen       Date:  2018-11-21       Impact factor: 2.911

9.  Synchronous Ovarian and Breast Cancers with a Novel Variant in BRCA2 Gene: A Case Report.

Authors:  Néstor Llinás-Quintero; Eduardo Cabrera-Florez; Gustavo Mendoza-Fandiño; Gustavo Matute-Turizo; Elsa M Vasquez-Trespalacios; Luis J Gallón-Villegas
Journal:  Case Rep Oncol Med       Date:  2019-01-06

Review 10.  Molecular subtypes and precision treatment of triple-negative breast cancer.

Authors:  Shen Zhao; Wen-Jia Zuo; Zhi-Ming Shao; Yi-Zhou Jiang
Journal:  Ann Transl Med       Date:  2020-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.